Advanced lung cancer inflammation index (ALI): A new pronostic score in patients with non small cell lung cancer

Bacha, S.; Mejdoub, Sabrine; Sghaier, Amani; Sonia, Habibach; Racil, H.; Cheikhrouhou, S.; Chaouch, N.; Chabbou, A.; Megdiche, M.L.

doi:10.1183/13993003.congress-2016.pa518

Cited by 6 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1. Ultimately, nine studies met our selection criteria; after excluding duplicated studies and reviewing the full texts of the manuscripts [25,[29][30][31][32][33][34][35][36], a total of 1736 cases were included. With respect to prognostic outcomes, nine studies reported OS, two studies reported progression-free survival, and one study reported disease-free survival.…”

Section: Study Selection and Characteristicsmentioning

confidence: 99%

Prognostic role of the advanced lung cancer inflammation index in cancer patients: a meta-analysis

Hua

Chen

et al. 2019

World J Surg Onc

View full text Add to dashboard Cite

Background: Inflammation plays a critical role in the development and progression of cancers. The advanced lung cancer inflammation index (ALI) is thought to be able to reflect systemic inflammation better than current biomarkers. However, the prognostic significance of the ALI in various types of cancer remains unclear. Our metaanalysis aimed to comprehensively investigate the relationship between the ALI and oncologic outcomes to help physicians better assess the prognosis of cancer patients. Methods: The PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, and Wanfang databases were searched for relevant studies. Hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated and pooled from the included studies. Furthermore, a sensitivity analysis was performed to evaluate the reliability of the articles. Finally, Begg's test, Egger's test, and the funnel plot were applied to assess the significance of publication bias. Results: In total, 1736 patients from nine studies were included in our meta-analysis. The median cutoff value for the ALI was 23.2 (range, 15.5-37.66) in the analyzed studies. The meta-analysis showed that there was a statistically significant relationship between a low ALI and worse overall survival (OS) in various types of cancer (HR = 1.70, 95% CI = 1.41-1.99, P < 0.001). Moreover, results from subgroup meta-analysis showed that the ALI had a significant prognostic value in non-small cell lung cancer, small cell lung cancer, colorectal cancer, head and neck squamous cell carcinoma, and diffuse large B cell lymphoma (P < 0.05 for all). Conclusions: These results showed that a low ALI was associated with poor OS in various types of cancer, and the ALI could act as an effective prognostic biomarker in cancer patients.

show abstract

Section: Study Selection and Characteristicsmentioning

confidence: 99%

Prognostic role of the advanced lung cancer inflammation index in cancer patients: a meta-analysis

Hua

Chen

et al. 2019

World J Surg Onc

View full text Add to dashboard Cite

show abstract

“…Our findings suggested that high level of inflammation was associated with better outcome in LUAD patients, which were consistent with previous studies. 10,11,13 We also found that the inflammation index tended to decrease with the increase of tumor stage, but it was not statistically significant. This phenomenon may be related to the dynamics and complexity of tumor inflammatory microenvironment.…”

Section: Discussionmentioning

confidence: 69%

“…11 In addition, low inflammatory index is associated with poor prognosis in metastatic non-small cell lung cancer. 13 However, inflammatory prognostic marker genes in LUAD have not been explored in these studies. In this study, we aimed to identify and verify the prognostic marker genes associated with inflammation.…”

Section: Introductionmentioning

confidence: 99%

Comprehensive Analysis to Identify Enhancer-Regulated Inflammation-Associated Genes in Lung Adenocarcinoma

Li¹,

Li²,

Ding³

2021

CMAR

View full text Add to dashboard Cite

The purpose of this study was to identify prognostic inflammatory markers regulated by enhancers in lung adenocarcinoma (LUAD). Methods: Inflammatory indices of 490 LUAD patients in TCGA database were calculated using genomic variation analysis (GSVA). Patients were divided into high-and lowinflammatory index groups. Fraction of 22 infiltrating immune cells was estimated using the Cell type Identification By Estimating Relative Subsets Of RNA Transcripts (CIBERSORT). Gene set enrichment analysis (GSEA) was used to analyze gene enrichment. Differentially expressed genes were screened based on TCGA database. The H3K27ac ChIPseq of A549 cells in GEO database (GSE42374) was analyzed to identify super enhancers. Kaplan-Meier method and multivariate Cox proportional hazards models were used for survival analysis. CCK8 and RT-qPCR were used for cellular level verification. Results: Inflammation was associated with better outcome in LUAD patients. Anti-cancer immune cell fractions were upregulated in high-inflammatory index group. Genes enriched in inflammation-related signaling pathways were positively correlated with high-inflammatory index group. A total of 146 upregulated genes regulated by enhancers were screened, of which five genes including GDF10, HPGDS, ABCA8, SLIT3 and ADAMTS8 had significant influence on prognosis. ChIP-seq analysis showed that TGFβ+TNFα treatment promoted the enhancer activation of the five genes. Cellular experiments revealed that there was no significant effect of TGFβ treatment on the five genes expression. TNFα treatment upregulated the five genes expression, while the BET-bromodomain inhibitor JQ1 restored the effect of TNFα. Overexpression of the five genes significantly inhibited the proliferation of A549 and H1299 cells. Conclusion: GDF10, HPGDS, ABCA8, SLIT3 and ADAMTS8 were identified as enhancer-regulated prognostic inflammation-related biomarkers, and the expression of these genes inhibited proliferation of LUAD cells.

show abstract

“…Similar to Tomita et al, (2018) who found that ALI < 37.66 was the predictive post-operative survival in patients with lung cancer who received surgery. Bacha et al, (2017) also discovered that ALI <18 was associated with poor prognosis in patients with metastatic lung cancer. However, Diaz De Teran Lopez et al, (2020) observed that the cut-off level at 37 was used in the metastatic stage.…”

Section: Discussionmentioning

confidence: 97%

Prognostic Impact of the Advanced Lung Cancer Inflammation Index (ALI) in Metastatic Non-Small Cell Lung Cancer Treated with First Line Chemotherapy

Chantharakhit¹,

Sujaritvanichpong²

2021

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Background:The advanced lung cancer inflammation index (ALI) has been reported to predict the overall survival in patients with advanced non-small cell lung cancer (NSCLC). However, no previous studies have examined the prognostic significance of ALI in metastatic NSCLC treated with first line chemotherapy. The objective of this study was to explore the relationship between ALI and the prognosis of metastatic NSCLC treated with first line chemotherapy. Materials and Methods: Data of 109 metastatic NSCLC patients who had completed first line treatment with chemotherapy was collected. A multivariate flexible parametric proportional-hazards model with restricted cubic splines (RCS) was used to explore and identify the independent prognostic factors, including clinical potential factors and ALI for the overall survival. Multivariate regression analysis was used to evaluate the potential prognostic factors associated with short survival less than 6 months. The analysis of the restricted mean survival time (RMST) method was used to estimate the event-free time from zero to 18 months. Results: The median OS was 10.9 months (95%CI 9.57-13.18) and median PFS was 7.5 months (95%CI 6.85-8.00).The multivariate survival analyses revealed two prognostic factors for worse survival: Poor ECOG PS (HR46.90; 95%CI 2.90-758.73; p=0.007) and progressive disease after completing the first line chemotherapy treatment (HR 2.85; 95%CI1.18-6.88; p=0.02),whereas a low ALI <11 referred to a non-significant prognostic factor (HR 1.42; 95%CI 0.67-3.01; p=0.364).The results of the multivariate regression analysis revealed that the low ALI and progressive disease status were significantly associated with the short survival outcome (OR 5.12; p=0.037; OR 12.57; 95%CI 3.00-52.73; p=0.001). Conclusions: A low ALI was associated with the short survival in metastatic NSCLC treated with chemotherapy. However, using ALI as a prognostic factor only was still too limited. Other considerable clinical prognostic factors should also be used simultaneously, which would have strong significant prognostic impacts.

show abstract

Advanced lung cancer inflammation index (ALI): A new pronostic score in patients with non small cell lung cancer

Cited by 6 publications

References 0 publications

Prognostic role of the advanced lung cancer inflammation index in cancer patients: a meta-analysis

Prognostic role of the advanced lung cancer inflammation index in cancer patients: a meta-analysis

Comprehensive Analysis to Identify Enhancer-Regulated Inflammation-Associated Genes in Lung Adenocarcinoma

Prognostic Impact of the Advanced Lung Cancer Inflammation Index (ALI) in Metastatic Non-Small Cell Lung Cancer Treated with First Line Chemotherapy

Contact Info

Product

Resources

About